Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

Rhea-AI Summary

Virax Biolabs (NASDAQ: VRAX) has received a notification from Nasdaq on July 14, 2025, regarding non-compliance with the minimum bid price requirement. The company's stock has traded below the required $1.00 minimum bid price for 30 consecutive business days.

The biotechnology company has been granted a 180-day compliance period until January 12, 2026, to regain compliance. Virax can achieve compliance if its stock maintains a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. If unsuccessful, the company may be eligible for an additional 180-day grace period. Meanwhile, VRAX shares will continue trading on Nasdaq without interruption.

Positive

• Potential eligibility for additional 180-day grace period if initial compliance period is not met
• Company's shares continue trading on Nasdaq without immediate delisting risk

Negative

• Stock price has fallen below $1.00 minimum bid requirement
• Risk of potential delisting from Nasdaq if compliance is not achieved by January 12, 2026
• Company must achieve significant stock price increase to maintain listing

News Market Reaction

+15.55% 4.1x vol

13 alerts

+15.55% News Effect

+6.8% Peak in 6 hr 19 min

+$608K Valuation Impact

$5M Market Cap

4.1x Rel. Volume

On the day this news was published, VRAX gained 15.55%, reflecting a significant positive market reaction. Argus tracked a peak move of +6.8% during that session. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $608K to the company's valuation, bringing the market cap to $5M at that time. Trading volume was very high at 4.1x the daily average, suggesting strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

LONDON, July 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced that it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") dated July 14, 2025, notifying the Company that it is not in compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)(2)(the "Minimum Bid Price Rule") for continued listing on the NASDAQ. 

NASDAQ Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of one hundred eighty (180) calendar days, or until January 12, 2026 (the "Compliance Period"), to regain compliance with Nasdaq's minimum bid price requirement. If at any time during the Compliance Period, the closing bid price per share of the Company's ordinary shares is at least $1.00 for a minimum of ten (10) consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed. In the event the Company does not regain compliance by January 12, 2026, the Company may be eligible for an additional 180 calendar day grace period.

The Nasdaq notification letter does not result in the immediate delisting of the Company's ordinary shares, and the shares will continue to trade uninterrupted under the symbol "VRAX."

About Virax Biolabs Group Limited.

Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.

For more information, please visit www.viraxbiolabs.com.

Caution Concerning Forward Looking Statements:

This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. These forward-looking statements are based on information currently available to Virax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Virax's Annual Report on Form 20-F for the year ended March 31, 2025. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

View original content to download multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-announces-receipt-of-nasdaq-notification-letter-regarding-minimum-bid-price-deficiency-302505259.html

SOURCE Virax BioLabs Group Limited

FAQ

Why did Virax Biolabs (VRAX) receive a Nasdaq deficiency notice?

Virax received the notice because its stock price traded below the required $1.00 minimum bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).

What is the deadline for Virax Biolabs to regain Nasdaq compliance?

Virax has until January 12, 2026 (180 calendar days) to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.

Will VRAX stock be delisted immediately from Nasdaq?

No, VRAX shares will continue trading on Nasdaq under the symbol 'VRAX' during the compliance period. The notification does not result in immediate delisting.

What happens if Virax Biolabs doesn't meet the January 2026 deadline?

If Virax fails to regain compliance by January 12, 2026, it may be eligible for an additional 180-day grace period to meet the minimum bid requirement.

How can Virax Biolabs regain Nasdaq compliance?

Virax can regain compliance if its stock maintains a closing bid price of at least $1.00 for a minimum of 10 consecutive business days during the compliance period.